Positive Outlook for Aquestive Therapeutics: Buy Rating Driven by Strong Pipeline, Financial Position, and Upcoming PDUFA Date

Analyst Francois Brisebois of LifeSci Capital reiterated a Buy rating on Aquestive Therapeutics, boosting the price target to $11.00.

Francois Brisebois has given his Buy rating due to a combination of factors surrounding Aquestive Therapeutics. The company’s recent financial results, with an EPS of ($0.14), were mostly in line with expectations, and there is optimism regarding the upcoming PDUFA date for Anaphylm on January 31, 2026. The absence of an Advisory Committee meeting and active FDA engagement suggest a clearer path to potential approval, supported by robust data demonstrating Anaphylm’s rapid absorption and convenience as a sublingual film.
Furthermore, Aquestive Therapeutics is making significant progress in its US commercial readiness efforts, including strategic leadership transitions and key commercial hires. The company’s pipeline remains strong, with the AQST-108 alopecia areata program on track under the guidance of the new Chief Development Officer. Additionally, the company’s financial position is bolstered by a strengthened balance sheet, with $129.1 million in cash as of September 30, 2025, following recent financing activities. These factors, along with growing awareness among allergists and positive interactions with regulatory bodies, contribute to the positive outlook and Buy rating for AQST.